Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-05-30 5:00 pm Purchase | 13D | Icosavax, Inc. ICVX | RA CAPITAL MANAGEMENT L.P. | 5,985,843 12.5% | 206,496 (+3.57%) | View |
| 2023-05-15 5:02 pm Sale | 13G | Travere Therapeutics, Inc. TVTX | RA CAPITAL MANAGEMENT L.P. | 0 0% | -3,984,681 (Position Closed) | View |
| 2023-05-15 5:01 pm Sale | 13G | DA32 Life Science Tech Acquisition Corp. DALS | RA CAPITAL MANAGEMENT L.P. | 0 0% | -1,500,000 (Position Closed) | View |
| 2023-05-15 5:01 pm Sale | 13G | ARYA Sciences Acquisition Corp V ARYE | RA CAPITAL MANAGEMENT L.P. | 0 0% | -1,000,000 (Position Closed) | View |
| 2023-04-18 4:30 pm Purchase | 13D | Satsuma Pharmaceuticals, Inc. STSA | RA CAPITAL MANAGEMENT L.P. | 5,944,252 17.9% | 30,000 (+0.51%) | View |
| 2023-04-10 5:05 pm Purchase | 13G | NanoString Technologies, Inc. NSTG | RA CAPITAL MANAGEMENT L.P. | 2,577,373 5.5% | 2,433,473 (+1691.09%) | View |
| 2023-04-10 5:01 pm Purchase | 13D | Eliem Therapeutics, Inc. ELYM | RA CAPITAL MANAGEMENT L.P. | 13,163,071 48.8% | 11,112 (+0.08%) | View |
| 2023-04-10 5:00 pm Purchase | 13G | Ascendis Pharma A/S ASND | RA CAPITAL MANAGEMENT L.P. | 9,967,172 17.4% | 3,009,993 (+43.26%) | View |
| 2023-03-30 5:08 pm Purchase | 13G | GH Research PLC GHRS | RA CAPITAL MANAGEMENT L.P. | 5,561,118 10.7% | 662,745 (+13.53%) | View |
| 2023-03-30 5:07 pm Purchase | 13D | Acrivon Therapeutics, Inc. ACRV | RA CAPITAL MANAGEMENT L.P. | 4,817,359 22% | 3,917 (+0.08%) | View |
| 2023-03-30 5:02 pm Purchase | 13D | 89bio, Inc. ETNB | RA CAPITAL MANAGEMENT L.P. | 12,876,898 18% | 3,500,496 (+37.33%) | View |
| 2023-03-29 5:14 pm Purchase | 13D | DICE Therapeutics, Inc. DICE | RA CAPITAL MANAGEMENT L.P. | 7,660,615 16.1% | 811,704 (+11.85%) | View |
| 2023-03-27 5:00 pm Purchase | 13G | CureVac N.V. CVAC | RA CAPITAL MANAGEMENT L.P. | 12,245,955 5.5% | 12,245,955 (New Position) | View |
| 2023-03-20 4:30 pm Purchase | 13G | Orchard Therapeutics plc ORTX | RA CAPITAL MANAGEMENT L.P. | 18,564,300 9.99% | 18,564,300 (New Position) | View |
| 2023-02-27 4:57 pm Sale | 13G | Enliven Therapeutics Inc. IMRA | RA CAPITAL MANAGEMENT L.P. | 2,122,465 5.2% | -1,128,259 (-34.71%) | View |
| 2023-02-24 4:30 pm Purchase | 13D | Mineralys Therapeutics, Inc. MLYS | RA CAPITAL MANAGEMENT L.P. | 3,180,920 7.8% | 3,180,920 (New Position) | View |
| 2023-02-14 4:45 pm Sale | 13G | Third Harmonic Bio, Inc. THRD | RA CAPITAL MANAGEMENT L.P. | 534,687 1.3% | -2,941,000 (-84.62%) | View |
| 2023-02-14 4:45 pm Purchase | 13G | Celcuity Inc. CELC | RA CAPITAL MANAGEMENT L.P. | 2,249,421 9.9% | 762,950 (+51.33%) | View |
| 2023-02-14 4:45 pm Sale | 13G | Ascendis Pharma A/S ASND | RA CAPITAL MANAGEMENT L.P. | 6,957,179 12.2% | -610,721 (-8.07%) | View |
| 2023-02-14 4:45 pm Purchase | 13G | CONCERT PHARMACEUTICALS INC. CNCE | RA CAPITAL MANAGEMENT L.P. | 5,199,746 9.99% | 1,689,643 (+48.14%) | View |